Kymera Therapeutics, Inc.

NasdaqGM KYMR

Kymera Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -148.20 M

Kymera Therapeutics, Inc. Free Cash Flow is USD -148.20 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 14.65% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Kymera Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -173.63 M, a -12.12% change year over year.
Kymera Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -154.87 M, a -36.81% change year over year.
Kymera Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -113.19 M, a -226.42% change year over year.
Kymera Therapeutics, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 89.54 M.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGM: KYMR

Kymera Therapeutics, Inc.

CEO	Dr. Nello Mainolfi M.D., Ph.D.
IPO Date	Aug. 21, 2020
Location	United States
Headquarters	200 Arsenal Yards Boulevard
Employees	184
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Key trends

Past 5 years